Androgenic steroids dysregulation and the risk of coronary artery disease

References

• Wu F, Eckardstein A. Androgens and coronary artery disease. Endocr Rev. 2003;24(2):183–217.
   PubMed Web of Science ®Google Scholar
• Goodale T, Sadhu A, Petak S, et al. Testosterone and the heart. Methodist Debakey Cardiovasc J. 2017;13(2):68–72.
   PubMedGoogle Scholar
• Imperlini E, Mancini A, Alfieri A, et al. Molecular effects of supraphysiological doses of doping agents on health. Mol Biosyst. 2015 Jun;11(6):1494–1506.
   PubMedGoogle Scholar
• Albano GD, Amico F, Cocimano G, et al. Adverse effects of anabolic-androgenic steroids: a literature review. Healthcare (Basel). 2021 Jan 19;9(1):97.
   PubMedGoogle Scholar
• Khaw KT, Dowsett M, Folkerd E, et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European Prospective Investigation Into Cancer in Norfolk (EPIC-Norfolk) prospective population study. Circulation. 2007;116(23):2694–2701.
   PubMed Web of Science ®Google Scholar
• Christou GA, Christou KA, Nikas DN, et al. Acute myocardial infarction in a young bodybuilder taking anabolic androgenic steroids: a case report and critical review of the literature. Eur J Prev Cardiol. 2016;23(16):1785–1796.
   PubMed Web of Science ®Google Scholar
• Khera M. Male hormones and men’s quality of life. Curr Opin Urol. 2016;26(2):152–157.
   PubMedGoogle Scholar
• Cauley JA, Gutai JP, Kuller LH, et al. Usefulness of sex steroid hormone levels in predicting coronary artery disease in men. Am J Cardiol. 1987;60(10):771–777.
   PubMedGoogle Scholar
• Arnlov J, Pencina MJ, Amin S, et al. Endogenous sex hormones and cardiovascular disease incidence in men. Ann Intern Med. 2006;145(3):176–184.
   PubMed Web of Science ®Google Scholar
• Shahidi NT. A review of the chemistry, biological action, and clinical applications of anabolic-androgenic steroids. Clin Ther. 2001;23(9):1355–1390.
   PubMed Web of Science ®Google Scholar
• Franey DG, Espiridion ED. Anabolic steroid-induced mania. Cureus. 2018;10(8):e3163.
   PubMedGoogle Scholar
• Sagoe D, Molde H, Andreassen CS, et al. The global epidemiology of anabolic-androgenic steroid use: a meta-analysis and meta-regression analysis. Ann Epidemiol. 2014;24(5):383–398.
   PubMed Web of Science ®Google Scholar
• Karolczak K, Konieczna L, Kostka T, et al. Testosterone and dihydrotestosterone reduce platelet activation and reactivity in older men and women. Aging (Albany NY). 2018;10(5):902–929.
   PubMedGoogle Scholar
• Ruige JB, Mahmoud AM, De Bacquer D, et al. Endogenous testosterone and cardiovascular disease in healthy men: a meta-analysis. Heart. 2011;97(11):870–875.
   PubMed Web of Science ®Google Scholar
• Mäkinen J, Järvisalo MJ, Pöllänen P, et al. Increased carotid atherosclerosis in andropausal middle-aged men. J Am Coll Cardiol. 2005;45(10):1603–1608.
   PubMed Web of Science ®Google Scholar
• Araujo AB, Dixon JM, Suarez EA, et al. Clinical review: endogenous testosterone and mortality in men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2011;96(10):3007–3019.
   PubMed Web of Science ®Google Scholar
• Lorigo M, Mariana M, Oliveira N, et al. Vascular pathways of testosterone: clinical implications. J Cardiovasc Transl Res. 2020 Feb;13(1):55–72. PMID: 31820333.
   PubMedGoogle Scholar
• Lorigo M, Mariana M, Lemos MC, et al. Vascular mechanisms of testosterone: the non-genomic point of view. J Steroid Biochem Mol Biol. 2020 Feb;196:105496.
   PubMed Web of Science ®Google Scholar
• English KM, Steeds RP, Jones TH, et al. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: a randomized, double-blind, placebo-controlled study. Circulation. 2000;102(16):1906–1911.
   PubMed Web of Science ®Google Scholar
• Rosano GM, Leonardo F, Pagnotta P, et al. Acute anti-ischemic effect of testosterone in men with coronary artery disease. Circulation. 1999;99(13):1666–1670.
   PubMed Web of Science ®Google Scholar
• Bhasin S, Storer TW, Berman N, et al. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med. 1996;335(1):1–7.
   PubMed Web of Science ®Google Scholar
• Maffei L, Murata Y, Rochira V, et al. Dysmetabolic syndrome in a man with a novel mutation of the aromatase gene: effects of testosterone, alendronate, and estradiol treatment. J Clin Endocrinol Metab. 2004;89(1):61–70.
   PubMedGoogle Scholar
• Sudhir K, Chou TM, Messina LM, et al. Endothelial dysfunction in a man with disruptive mutation in oestrogen-receptor gene. Lancet. 1997;349(9059):1146–1147.
   PubMedGoogle Scholar
• Anawalt B. Diagnosis and management of anabolic androgenic steroid use. J Clin Endocrinol Metab. 2019;104(7):2490–2500.
   PubMedGoogle Scholar
• Muller M, van den Beld AW, Bots ML, et al. Endogenous sex hormones and progression of carotid atherosclerosis in elderly men. Circulation. 2004;109(17):2074–2079.
   PubMed Web of Science ®Google Scholar
• Budoff MJ, Ellenberg SS, Lewis CE, et al. Testosterone treatment and coronary artery plaque volume in older men with low testosterone. JAMA. 2017;317(7):708–716.
   PubMedGoogle Scholar
• Svartberg J, von Mühlen D, Mathiesen E, et al. Low testosterone levels are associated with carotid atherosclerosis in men. J Intern Med. 2006;259(6):576–582.
   PubMed Web of Science ®Google Scholar
• Creatsa M, Armeni E, Stamatelopoulos K, et al. Circulating androgen levels are associated with subclinical atherosclerosis and arterial stiffness in healthy recently menopausal women. Metabolism. 2012;61(2):193–201.
   PubMedGoogle Scholar
• Zhao D, Guallar E, Ouyang P, et al. Endogenous sex hormones and incident cardiovascular disease in post-menopausal women. J Am Coll Cardiol. 2018;71(22):2555–2566.
   PubMed Web of Science ®Google Scholar
• Vaidya D, Dobs A, Gapstur S, et al. The association of endogenous sex hormones with lipoprotein subfraction profile in the multi-ethnic study of atherosclerosis (mesa). Metabolism. 2008;57(6):782–790.
   PubMedGoogle Scholar
• Zmuda J, Cauley J, Danielson M, et al. Longitudinal relation between endogenous testosterone and cardiovascular disease risk factors in middle-aged men. A 13-year follow-up of former multiple risk factor intervention trial participants. Am J Epidemiol. 1997;146(8):609–617.
   PubMed Web of Science ®Google Scholar
• Mäkinen JI, Perheentupa A, Irjala K, et al. Endogenous testosterone and serum lipids in middle-aged men. Atherosclerosis. 2008;197(2):688–693.
   PubMed Web of Science ®Google Scholar
• Liu HH, Li JJ. Aging and dyslipidemia: a review of potential mechanisms. Ageing Res Rev. 2015;19:43–52.
   PubMed Web of Science ®Google Scholar
• Langer C, Gansz B, Goepfert C, et al. Testosterone up-regulates scavenger receptor BI and stimulates cholesterol efflux from macrophages. Biochem Biophys Res Commun. 2002;296(5):1051–1057.
   PubMed Web of Science ®Google Scholar
• Heemers H, Maes B, Foufelle F, et al. Androgens stimulate lipogenic gene expression in prostate cancer cells by activation of the sterol regulatory element-binding protein cleavage activating protein/sterol regulatory element-binding protein pathway. Mol Endocrinol. 2001;15(10):1817–1828.
   PubMedGoogle Scholar
• Achar S, Rostamian A, Narayan SM. Cardiac and metabolic effects of anabolic-androgenic steroid abuse on lipids, blood pressure, left ventricular dimensions, and rhythm. Am J Cardiol. 2010;106(6):893–901.
   PubMed Web of Science ®Google Scholar
• Peoples K, Kobe D, Campana C, et al. Hyperhomocysteinemia-induced myocardial infarction in a young male using anabolic steroids. Am J Emerg Med. 2014;32(8):948.e1–2.
   Google Scholar
• Lippi G, Banfi G. Doping and thrombosis in sports. Semin Thromb Hemost. 2011;37(8):918–928.
   PubMedGoogle Scholar
• Ajayi AA, Mathur R, Halushka PV. Testosterone increases human platelet thromboxane A2 receptor density and aggregation responses. Circulation. 1995;91(11):2742–2747.
   PubMed Web of Science ®Google Scholar
• Corona G, Rastrelli G, Vignozzi L, et al. Testosterone, cardiovascular disease and the metabolic syndrome. Best Pract Res Clin Endocrinol Metab. 2011;25(2):337–353.
   PubMed Web of Science ®Google Scholar
• English KM, Mandour O, Steeds RP, et al. Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms. Eur Heart J. 2000;21(11):890–894.
   PubMed Web of Science ®Google Scholar
• Petering RC, Brooks NA. Testosterone therapy: review of clinical applications. Am Fam Physician. 2017;96(7):441–449.
   PubMed Web of Science ®Google Scholar
• Uzunova AD, Ramey ER, Ramwell PW. Arachidonate-induced thrombosis in mice: effects of gender or testosterone and estradiol administration. Prostaglandins. 1977;13(5):995–1002.
   PubMedGoogle Scholar
• Alqahtani SA, Alhawiti NM. Administration of testosterone improves the prothrombotic and antifibrinolytic parameters associated with its deficiency in an orchidectiomized rat model. Platelets. 2019;30(5):624–630.
   PubMed Web of Science ®Google Scholar
• Brenu EW, McNaughton L, Marshall-Gradisnik SM. Is there a potential immune dysfunction with anabolic androgenic steroid use?: a review. Mini Rev Med Chem. 2011;11(5):438–445.
   PubMedGoogle Scholar
• Johnson M, Ramey E, Ramwell PW. Androgen-mediated sensitivity in platelet aggregation. Am J Physiol. 1977;232(4):H381–5.
   PubMed Web of Science ®Google Scholar
• Rosenblum WI, el-Sabban F, Nelson GH, et al. Effects in mice of testosterone and dihydrotestosterone on platelet aggregation in injured arterioles and ex vivo. Thromb Res. 1987;45(6):719–728.
   PubMedGoogle Scholar
• Matsuda K, Ruff A, Morinelli TA, et al. Testosterone increases thromboxane A2 receptor density and responsiveness in rat aortas and platelets. Am J Physiol. 1994;267(3 Pt 2):H887–93.
   PubMedGoogle Scholar
• Ajayi AAL, Halushka PV. Castration reduces platelet thromboxane A2 receptor density and aggregability. Qjm. 2005;98(5):349–356.
   PubMed Web of Science ®Google Scholar
• Banerjee D, Mazumder S, Bhattacharya S, et al. The sex specific effects of extraneous testosterone on ADP induced platelet aggregation in platelet-rich plasma from male and female subjects. Int J Lab Hematol. 2014;36(5):e74–7.
   PubMedGoogle Scholar
• Spranger M, Aspey BS, Harrison MJ. Sex difference in antithrombotic effect of aspirin. Stroke. 1989;20(1):34–37.
   PubMedGoogle Scholar
• Kelly DM, Jones TH. Testosterone: a vascular hormone in health and disease. J Endocrinol. 2013;217(3):47–71.
   PubMed Web of Science ®Google Scholar
• Hotta Y, Kataoka T, Kimura K. Testosterone deficiency and endothelial dysfunction: nitric oxide, asymmetric dimethylarginine, and endothelial progenitor cells. Sex Med Rev. 2019;7(4):661–668.
   PubMed Web of Science ®Google Scholar
• Kienitz T, Quinkler M. Testosterone and blood pressure regulation. Kidney Blood Press Res. 2008;31(2):71–79.
   PubMedGoogle Scholar
• Jones RD, Hugh Jones T, Channer KS. The influence of testosterone upon vascular reactivity. Eur J Endocrinol. 2004;151:29–37.
   PubMed Web of Science ®Google Scholar
• Gur S, Alzweri L, Yilmaz-Oral D, et al. Testosterone positively regulates functional responses and nitric oxide expression in the isolated human corpus cavernosum. Andrology. 2020 Jul 16;1824–1833. DOI:https://doi.org/10.1111/andr.12866.
   Google Scholar
• Lafayette SS, Vladimirova I, Garcez-do-Carmo L, et al. Evidence for the participation of calcium in non-genomic relaxations induced by androgenic steroids in rat vas deferens. Br J Pharmacol. 2008;153(6):1242–1250.
   PubMedGoogle Scholar
• Deenadayalu VP, White RE, Stallone JN, et al. Testosterone relaxes coronary arteries by opening the large-conductance, calcium-activated potassium channel. Am J Physiol Heart Circ Physiol. 2001;281(4):H1720–7.
   PubMed Web of Science ®Google Scholar
• Wynne FL, Khalil RA. Testosterone and coronary vascular tone: implications in coronary artery disease. J Endocrinol Invest. 2003;26(2):181–186.
   PubMedGoogle Scholar